Nomura Asset Management Co. Ltd. Has $45.35 Million Position in Insulet Corporation $PODD

Nomura Asset Management Co. Ltd. boosted its stake in shares of Insulet Corporation (NASDAQ:PODD) by 285.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 159,549 shares of the medical instruments supplier’s stock after acquiring an additional 118,138 shares during the quarter. Nomura Asset Management Co. Ltd. owned 0.23% of Insulet worth $45,350,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in shares of Insulet by 1.0% during the third quarter. Vanguard Group Inc. now owns 8,796,200 shares of the medical instruments supplier’s stock worth $2,715,651,000 after purchasing an additional 87,845 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Insulet by 2.1% during the fourth quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock worth $568,274,000 after purchasing an additional 41,019 shares during the last quarter. Norges Bank bought a new stake in shares of Insulet during the fourth quarter worth $300,794,000. Northern Trust Corp grew its holdings in shares of Insulet by 0.5% during the third quarter. Northern Trust Corp now owns 709,180 shares of the medical instruments supplier’s stock worth $218,945,000 after purchasing an additional 3,618 shares during the last quarter. Finally, Qube Research & Technologies Ltd grew its holdings in shares of Insulet by 37.3% during the third quarter. Qube Research & Technologies Ltd now owns 574,365 shares of the medical instruments supplier’s stock worth $177,324,000 after purchasing an additional 156,009 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on PODD shares. Bank of America decreased their target price on Insulet from $288.00 to $208.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Evercore decreased their target price on Insulet from $240.00 to $200.00 in a report on Thursday, May 7th. Rothschild & Co Redburn restated a “neutral” rating and set a $220.00 target price (down from $380.00) on shares of Insulet in a report on Friday, April 24th. Raymond James Financial decreased their target price on Insulet from $355.00 to $263.00 in a report on Thursday, May 7th. Finally, Jefferies Financial Group decreased their target price on Insulet from $400.00 to $360.00 in a report on Thursday, May 7th. Twenty-one investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $252.04.

Insulet Price Performance

Insulet stock opened at $144.94 on Monday. The business’s 50-day simple moving average is $183.55 and its 200 day simple moving average is $244.77. The stock has a market cap of $10.04 billion, a price-to-earnings ratio of 33.71, a P/E/G ratio of 1.14 and a beta of 1.13. Insulet Corporation has a 12-month low of $140.63 and a 12-month high of $354.88. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.23. The business had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm’s quarterly revenue was up 33.9% compared to the same quarter last year. During the same quarter last year, the business earned $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, research analysts anticipate that Insulet Corporation will post 6.44 earnings per share for the current year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.